Wintermute Biomedical are excited our ZosterEase Phase Ib clinical trial’s patient recruitment is now fulfilled.
Preliminary safety results expected shortly. Read more here.
Preliminary safety results expected shortly. Read more here.
Education
This episode details the findings of our study investigating the antiviral properties of GS-1, a new compound combining undecylenic acid and L-Arginine. The research focuses on GS-1's effectiveness against herpes viruses, specifically Varicella-Zoster Virus (VZV) and Herpes Simplex Virus (HSV), both of which pose significant global health challenges and for which current treatments have limitations.
The study demonstrates that GS-1 exhibits antiviral activity by preventing viral particles from entering host cells. Experiments show GS-1's efficacy in laboratory settings and in an ex vivo human skin model, suggesting its potential as a topical antiviral therapy with a distinct mechanism compared to existing drugs. The authors propose that GS-1 could offer advantages in controlling viral infections and reducing transmission.
Listen to this audio clip for an overview of how GS-1 (Solexan™) acts against herpesviruses.
Read the full publication here.
Note: This audio clip was generated using AI to provide a clear and engaging overview of this topic. We value your feedback—let us know what you think.